

CERTIFICATE OF ELECTRONIC TRANSMISSION

37 C.F.R. § 1.8

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

October 31, 2007 Electronic signature: / Svitlana Anderson /
Date Svitlana Anderson

PTO/SB/44 (09-07)
Approved for use through 08/31/2010. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
(Also Form PTO-1050)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,008,633
APPLICATION NO. : 10/024,678
ISSUE DATE : March 7, 2006
INVENTOR(S) : David J. Yang et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On cover page, left column, under [75] Inventors: . . . Ali Azhdarinia, Houston, TX (US) should be on the same line.
On cover page, left column, under [75] Inventors: . . . E. Edmund Kim, Houston, TX (US) should be on the same line.
In Col. 67, line 56, after the third occurrence of "hormone" insert -- releasing hormone-- .
In Col. 67, line 59, after "gonadotropin" insert -- , somatotropin, somatostatin, somatotropin releasing hormone, gonadotropin --
In Col. 67, line 67, "erthropoetin" should read -- erythropoietin --.
In Col. 68, line 1 "estrdiol" should read -- estradiol --.
In Col. 68, line 5 "enkaeophalin" should read -- enkephalin --.
In Col. 68, line 10 "platlet-derived" should read -- platelet-derived --.
In Col. 68, lines 22-23 "*ras ; myc, raf, erb, src, fms, jun, trk, ret, gsp, hst, bcl abl,*" apply Italic font.
In Col. 68, line 24 "ras" apply Italic font.
In Col. 68, line 33, after the occurrence of "claim" delete "of".
In Col. 68, line 41, "bromelam" should read -- bromelain --.
In Col. 68, line 44, "aurantiurn" should read -- aurantium --.
In Col. 68, line 58, "picrorbiza" should read -- picrorhiza
In Col. 68, line 61, "chiorophyllin" should read -- chlorophyllin --.
In Col. 68, line 66, "in situ" apply Italic font.
In Col. 69, line 5, "in situ" apply Italic font.
In Col. 69, line 6, "cross linked" should read "cross-linked".
In Col. 69, line 10, after the "container" insert --the cross-linking composition. --.
In Col. 69, line 34, "polyainino" should read -- polyamino --.
In Col. 70, line 2, "vinbiastine" should read -- vinblastine --.
In Col. 70, line 3, "meiphalan" should read -- melphalan --.
In Col. 70, line 3 "chiorambucil" should read -- In Col. 70, line 5, "azireonani" should read -- In Col. 70, line 20, "acetyicholine" should read -- acetylcholine --.
In Col. 70, line 22, "chymodemn" should read -- chymodenin --.
In Col. 70, line 26, "choriomc" should read -- chorionic --.
In Col. 70, line 29, "lysyibradykinin" should read -- lysylbradykinin --.
In Col. 70, line 37, "P." should read -- P, --.
In Col. 70, line 46-47, "*ras ; myc, raf, erb, src, fms, jun, trk, ret, gsp, hst, bcl abl, Rb,*" apply Italic font.

55100292.1

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Melissa L. Sistrunk, Ph. D. Reg. No. 45,579

FULBRIGHT & JAWORSKI L.L.P.

1

Fulbright Tower

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

